ELECTROCORE INC
ECORNASDAQTrading Snapshot
- Day Range
- $10.76 – $11.07
- 52-Week Range
- $4.41 – $12.70
- Volume
- $6.37B
- Avg Volume
- $4.46B
- Shares Outstanding
- 9.0M
- Next Earnings
- Nov 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $32M
- Last Q Revenue
- $9M
- P/E Ratio
- -6.4
- P/S Ratio
- 2.7x
- EPS (TTM)
- $-1.57
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +7.0%
Why Investors Own ECOR
- ✓High-growth profile — revenue up +59.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 45% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ELECTROCORE INC
ECOR
StockOtter · stockotter.spaceAbout ELECTROCORE INC
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
electroCore Has A Line Of Sight At Cash Breakeven
electroCore is showing operational and financial improvement, driven by sales force expansion and strong Quell Fibromyalgia growth. ECOR targets >30% FY26 revenue growth, 85%+ gross margins, and positive adjusted EBITDA
Thomas Errico Purchases 5,000 Shares of electroCore (NASDAQ:ECOR) Stock
electroCore, Inc. (NASDAQ: ECOR - Get Free Report) Director Thomas Errico bought 5,000 shares of the company's stock in a transaction dated Monday, September 14th. The stock was bought at an average price of $9.82 per sh
electroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar?
electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
electroCore to Participate at H.C. Wainwright Global Investment Conference
ROCKAWAY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the H.C.
electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers
ROCKAWAY, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today a
electroCore's Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards
Recognition highlights Truvaga's combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experience Recognition highlights Truvaga's combination of patented no